Results: Remdesivir sales affect Gilead
Gilead published stable results in 2022, at $27.3bn (€25.5bn). Stagnation largely due to Veklury (remdesivir), its treatment for severe forms of Covid-19, whose sales fell by 30%. Gilead can still be satisfied with its best seller, the Biktarvy triple therapy, indicated once morest HIV, which reached $10.4 billion in sales (+ 20%). In this same indication, Descovy (emtricitabine, tenofovir) is also up 10%. For 2023, Gilead anticipates sales of between $26 and $26.5 billion.
VOS INDICES
source
Results: Lilly remains constant in 2022
Little change for the American laboratory in 2022. Compared to 2021, the turnover of Lilly is up very slightly, less than 1%, to 28.54 billion dollars (26.76 billion €). On the portfolio side, Trulicity (dulaglutide) ($7.4 billion, +15%), positioned on diabetes, remains the group’s best-selling drug. Big progress for Verzenio (abemaciclib), an inhibitor indicated once morest breast cancer, which jumped 84% to $2.48 billion. On the other hand and logically, the laboratory’s antibodies once morest Covid-19 fell by 9.6% to $2 billion, due to the evolution of the pandemic. There was also a big decline for Alimta (pemetrexed), which reached $927.7 million, ie a discount of 55%.
For 2023, Lilly wants to be optimistic and is counting on the Mounjaro (tirzepatide) launched for type 2 diabetes in 2022 to generate growth. The laboratory also wants to bet on the evolution of its pipeline, as indicated by David A. Ricks, CEO of Lilly: “In this critical year, we hope to launch up to four new disease drugs, while advancing our next generation of molecules currently in Phase III. »
CDMO: Evotec obtains a €150 million loan from the EIB
The German group Evotec receives weight support. The CDMO has just obtained a loan of 150 million euros from the European Investment Bank (EIB). Funds which will be used in particular for the construction of a factory in Toulouse of its subsidiary dedicated to bioproduction Just Evotec Biologics. Called J.Pod Toulouse, this plant is intended to be the European counterpart of the site opened by Evotec in the United States in 2021. The first stone was laid in September 2022 (link to the article) and the future Toulouse site should be operational in 2024.
“This EIB investment will also have a significant impact on activity in the Toulouse region, as it will contribute to the financing of a 12,000 square meter factory which will create more than 200 highly qualified jobs. », welcomed Ambroise Fayolle, Vice-President of the EIB. The funds will also be used to support Evotec’s R&D activities and its equity investments. In 2017, Evotec had already obtained a first loan of €75 million from the EIB.
Selected for you
